Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 12, 2009, Pages 1537-1543

  Reynolds, Craig ^a,b   Barrera, David ^a,c   Jotte, Robert ^a,d   Spira, Alexander I ^a,e   Weissman, Charles ^a,f   Boehm, Kristi A ^a   Pritchard, Sharon ^a   Asmar, Lina ^a  

^a US Oncology Research Inc   (United States)

^b Ocala Oncology   (United States)

^c Texas Cancer Center   (United States)

^d ROCKY MOUNTAIN CANCER CENTERS   (United States)

^e Fairfax Northern Virginia Hematology Oncology   (United States)

^f New York Oncology Hematology   (United States)

Author keywords

Metastatic; Monoclonal; Multicenter; Paclitaxel; Platinum

Indexed keywords

ALBUMIN; BEVACIZUMAB; CARBOPLATIN; CREMOPHOR; NANOPARTICLE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DEMOGRAPHY; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FACE EDEMA; FEMALE; HEMOPTYSIS; HUMAN; HYPERKALEMIA; INFECTION; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING; WEAKNESS;

EID: 74249105385     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c0a2f4     Document Type: Article

References (33)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
2. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-smallcell lung cancer and a performance status of 2. J Clin Oncol 2008;26: 863-869.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
4. Reck M, von Pweel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
5. Bristol-Myers Squibb. Taxol Package Insert (rev July 2007). Available at: http://packageinserts.bms.com/pi/pi-taxol.pdf. Accessed March 9, 2009.
6. Desai N, Trieu V, Yao R, Labao E, Soon-Shiong P. Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (ABI-007) by gp60-receptors: a pathway inhibited by taxol. Presented at the 2004 San Antonio Breast Cancer Symposium, San Antonio, TX. December 8, 2004, Abstract 1071.
7. Desai N, Trieu V, Yao R, Frankel T, Soon-Shiong P. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Presented at the 2004 San Antonio Breast Cancer Symposium, San Antonio, TX. December 8, 2004, Abstract 206.
8. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-1044.
9. Robinson DM, Keating GM. Albumin-bound paclitaxel: in metastatic breast cancer. Drugs 2006;66:941-948.
10. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27: 3611-3619
11. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared With polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
12. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008; 26:639-643.
13. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophorfree, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:1263-1268.
14. Allerton JP, Hagenstad CT, Webb RT, et al. A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24:Abstract 7127.
15. Hawkins MJ, Georgy M, Makhson A, et al. Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24:Abstract 7132.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;95:205-216. (Pubitemid 30099779)
17. National Cancer Institute. Common Terminology Criteria for Adverse Event version 3.0. (CTCAE). Available at: http://ctep.cancer.gov/reporting/ ctc-v30.html. Accessed August 13, 2008.
18. FACIT Functional Assessment of Chronic Illness Therapy, FACTTaxane Questionnaire v4. Available at: http://www.facit.org/qview/ qlist.aspx (FACT-Taxane-us-sample-pdf[1].pdf). Accessed January 23, 2008.
19. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Acoust Soc Am 1958;53:457-481.
21. Genentech press release. Available at: http://www.gene.com/gene/news/ press-releases/display.do?method-detail&id-8427. Accessed April 13, 2009.
22. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-8139.
23. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
24. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003;284: L187-L196.
25. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003;14:3977-3988.
26. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI-007, compared with cremophorbased paclitaxel. Clin Cancer Res 2006;12:1317-1324.
27. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-325.
28. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Upregulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002;161: 1647-1656.
29. Kato K, Hida Y, Miyamoto M, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002;94:929-933.
30. Tahir SA, Yang G, Ebara S, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001;61:3882-3885.
31. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000;6:1140-1149.
32. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. In press.
33. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.